Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17239092 | 0.84 | HDAC6 (0.38) | PRMT5WDR77HRH3CSF1RFLT3 | |
| SCHEMBL444738 | 0.82 | HPGD (0.44) | PRMT5WDR77CSF1RFLT3NAMPT | |
| SCHEMBL4815442 | 0.80 | NAMPT (0.39) | PRMT5WDR77HRH3CSF1RFLT3 | |
| SCHEMBL4251736 | 0.75 | HPGD (0.42) | PRMT5WDR77HRH3CSF1RFLT3 | |
| SCHEMBL4247743 | 0.74 | NAMPT (0.39) | PRMT5WDR77HRH3CSF1RFLT3 | |
| SCHEMBL444531 | 0.71 | HRH3 (0.42) | HRH3HDAC6 | |
| SCHEMBL444532 | 0.71 | HRH3 (0.42) | HRH3HDAC6 | |
| SCHEMBL444240 | 0.70 | TAS1R3 (0.46) | HRH3 | |
| SCHEMBL443139 | 0.69 | HDAC3 (0.41) | PRMT5WDR77HRH3HDAC6 | |
| SCHEMBL444241 | 0.69 | TAS1R3 (0.49) | HRH3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | PRMT5 1089/4885WDR77 1384/4885HRH3 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.